On 28 April 2026, Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) approved the issuance of 4.99 million restricted share units (RSUs) to 804 participants under its Post-IPO RSU Scheme adopted in May 2019.

The allocation comprises 109,010 RSUs to Executive Director Dr. Lyu Aifeng and 4.88 million RSUs to 803 employees across the Group. Independent non-executive directors have endorsed the grant to Dr. Lyu; no shareholder approval is required as the award forms part of his service-contract remuneration and involves only existing shares held by the scheme’s trustee.

Key terms: • Purchase price: HK$7.8592 per share • Market price on grant date: HK$37.30 per share • Vesting start: 29 April 2026 • Vesting schedule: about 34 % after one year, 33 % after two years, and the final 33 % after three years

Vesting is subject to performance conditions linked to both corporate results and individual KPIs, alongside clawback provisions covering compliance breaches, quality incidents, unmet targets, or employment termination. No loans or other financial assistance will be provided to the grantees.

Post-grant, the scheme retains capacity for awards representing up to 34.84 million shares. The company will apply the transitional provisions of the revised Chapter 17 of the Hong Kong Listing Rules to future grants.